FCH
BMRN icon

Freestone Capital Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Freestone Capital Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,987
Closed -$539K – 449
2022
Q1 		$539K Sell
6,987
-1,822
-21% -$152K 0.02% 331
2021
Q4 		$778K Buy
8,809
+353
+4% +$29.1K 0.03% 262
2021
Q3 		$654K Sell
8,456
-788
-9% -$62.2K 0.03% 257
2021
Q2 		$771K Sell
9,244
-301
-3% -$23.9K 0.04% 236
2021
Q1 		$721K Buy
9,545
+490
+5% +$40K 0.04% 241
2020
Q4 		$794K Sell
9,055
-437
-5% -$34.6K 0.05% 211
2020
Q3 		$722K Sell
9,492
-378
-4% -$38.2K 0.05% 203
2020
Q2 		$1.22K Buy
9,870
+895
+10% +$89K 0.01% 187
2020
Q1 		$758 Buy
8,975
+1,490
+20% +$128K 0.02% 212
2019
Q4 		$633 Sell
7,485
-1,331
-15% -$101K 0.01% 296
2019
Q3 		$594 Buy
8,816
+524
+6% +$40.4K 0.01% 303
2019
Q2 		$710 Buy
8,292
+829
+11% +$70.9K 0.02% 262
2019
Q1 		$663K Buy
7,463
+3,665
+96% +$340K 0.04% 256
2018
Q4 		$323K Buy
+3,798
New +$361K 0.02% 333

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Freestone Capital Holdings's BMRN Position: Q2 2022 in Review

Freestone Capital Holdings sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 6,987 shares — an estimated $539K sold.

Freestone Capital Holdings first reported a position in BMRN in Q4 2018 and held it in 14 quarters. The position peaked at $794K in Q4 2020. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

  • Freestone Capital Holdings reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Freestone Capital Holdings sold 6,987 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $539K.
  • Freestone Capital Holdings first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 14 quarters.
  • Freestone Capital Holdings's BioMarin Pharmaceuticals position peaked at $794K in Q4 2020.
  • 542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Freestone Capital Holdings's 13F filing for Q2 2022, filed 9 Aug 2022.